American Brain Tumor Consortium Study1

Neuro-Oncology This phase II study in recurrent high-grade glioma evalu-ated the response rate, toxicities, and time to treatment failure of high-dose carboplatin modulated by a 24-h infusion of thymidine (75 g/m2). The trial was based on preclinical data and a prior phase I study ( J. Clin. Oncol. 17, 2922-2931, 1999); a phase II recurrent high-grade glioma study was initiated in July of 1998. Thymidine was given over 24 h; carboplatin was given over 20 min at hour 20 of the thymidine infusion. The starting dose of carboplatin had a value of 7 for the area under the curve (AUC), with allowance for dose escalation of 1 AUC unit per cycle if grade 2 toxicity was observed. Treatment cycles were repeated every 4 weeks. Accrual as of Sep-tember 1999 was 45 patients [4 were unevaluable]: 76% A phase II trial of thymidine and carboplatin for recurrent malignant glioma: A Nort